Clinical trial
CP-724,714 in Treating Patients With Metastatic Breast Cancer
NCT00055926 · Jonsson Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00055926 |
|---|---|
| Title | CP-724,714 in Treating Patients With Metastatic Breast Cancer |
| Official title | A Phase I Safety and Pharmacokinetic/Pharmacodynamic Study of CP-724, 714 In Patients With Metastatic HER2-Overexpressing Breast Cancer |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | CP-724, 714 |
| Enrollment | 9 |
| Start date | Jan 1, 2003 |
| Primary completion | Dec 1, 2004 |
| Completion | May 1, 2005 |
| First posted | Mar 7, 2003 |
| Last update posted | Aug 3, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: